Venture: European Speciality Pharma
Issue 35;
Personalised Drugs
The speciality pharmaceutical industry focuses on high-cost, complex care therapies for patients with challenging disease states.
Medications range from oral to cutting-edge injectable and biologic products, which often carry high risks of side effects, and can be personalised to the patient’s needs. The drugs themselves may require special handling, such as cold storage, and patients who use them may need to work closely with doctors, pharmacists, and other healthcare providers who can monitor their progress. This complexity adds cost and raises high barriers to entry for new competitors. Swift and high-quality distribution networks, patient interactions, and regulatory expertise are critical.
The ageing population is increasing the incidence of these complex maladies, and as such speciality pharma is a growing and well-defended industry for existing operators. It's an 8% p.a. growth market with high barriers to entry, and one company is breaking out.
Venture is issued by ByteTree Asset Management Ltd, an appointed representative of Strata Global which is authorised and regulated by the Financial Conduct Authority. ByteTree Asset Management is a wholly owned subsidiary of CryptoComposite Ltd.
General - Your capital is at risk when you invest, never risk more than you can afford to lose. Past performance and forecasts are not reliable indicators of future results. Bid/offer spreads, commissions, fees and other charges can reduce returns from investments. There is no guarantee dividends will be paid. Overseas shares - Some recommendations may be denominated in a currency other than sterling. The return from these may increase or decrease as a result of currency fluctuations. Any dividends will be taxed at source in the country of issue.
Funds - Fund performance relies on the performance of the underlying investments, and there is counterparty default risk which could result in a loss not represented by the underlying investment. Exchange Traded Funds (ETFs) with derivative exposure (leveraged or inverted ETFs) are highly speculative and are not suitable for risk-averse investors.
Bonds - Investing in bonds carries interest rate risk. A bondholder has committed to receiving a fixed rate of return for a fixed period. If the market interest rate rises from the date of the bond's purchase, the bond's price will fall. There is also the risk that the bond issuer could default on their obligations to pay interest as scheduled, or to repay capital at the maturity of the bond.
Taxation - Profits from investments, and any profits from converting cryptocurrency back into fiat currency is subject to capital gains tax. Tax treatment depends on individual circumstances and may be subject to change.
Investment Director: Charlie Morris. Editors or contributors may have an interest in recommendations. Information and opinions expressed do not necessarily reflect the views of other editors/contributors of CryptoComposite Ltd. ByteTree Asset Management (FRN 933150) is an Appointed Representative of Strata Global Ltd (FRN 563834), which is regulated by the Financial Conduct Authority.
© 2024 Crypto Composite Ltd
